太古(00019.HK)附屬擬在奧斯陸交易所上市
太古(00019.HK)公布,有關於全資附屬太古海洋開發建議將其附屬公司Swire Blue Ocean A/S(已更名為Cadeler A/S)於挪威奧斯陸證券交易所上市的事宜,Cadeler已於挪威宣佈進行首次公開發售之建議條款。在首次公開發售中將會出售的股份包括Cadeler將予發行的新股及太古海洋開發將會出售的Cadeler現有股份。太古海洋開發將會出售的股份數量將隨市場需求而改變。
太古海洋開發將不會在首次公開發售完成後持有Cadeler超過50%股份,而所得款項總額介乎1.6億至1.87億美元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.